摘要
目的探讨PD-1免疫检查点抑制剂信迪利单抗致免疫相关不良反应的特点以及临床药师参与新型抗肿瘤药物治疗实践的模式。方法分析信迪利单抗致甲状腺功能减退和血小板减少病例各1例,探讨信迪利单抗致两种不良反应的特点,开展药学监护,协助制定不良反应处理方案。结果临床医生接受药师建议,甲状腺功能减退患者甲状腺功能逐步恢复并完成抗肿瘤治疗疗程,血小板减少患者血小板水平恢复至正常范围,安全度过化疗期。结论新型抗肿瘤药物PD-1免疫检查点抑制剂临床应用日益广泛,临床药师可通过药物不良反应这一切入点,参与新型抗肿瘤药物临床治疗实践,提高用药安全性。
Objective To explore the characteristics of immue-related adverse events induced by sintilimab and the mode of clinical pharmacists participating in therapy of novel antitumor drugs.Methods One case of hypothyroidism and one of thrombocytopenia induced by sintilimab was analyzed respectively,and the characteristics of the two adverse effects were explored.Pharmaceutical care was carried out by the clinical pharmacists,who helped to solve out the adverse effects.Results Suggestions of the clinical pharmacists were accepted by clinicians.Thyroid function of the patient who suffered from hypothyroidism was recovered gradually and completed the anti-tumor treatment.Platelet level returned to normal range in the patient,who lived safely through chemotherapy.Conclusion PD-1 inhibitor has been more and more widely used as a novel antitumor drug,and characteristics differ in different immue-related adverse events,which can be a breakthrough point in clinical treatment practice with novel anti-tumor drugs of clinical pharmacists,who aim to improve the safety of the drugs.
作者
梅丹
倪美鑫
顾海娟
郭小红
顾翩翩
MEI Dan;NI Mei-xin;GU Hai-juan;GUO Xiao-hong;GU Pian-pian(Department of Pharmacy,Affiliated Tumor Hospital of Nantong University,Nantong 226361,China)
出处
《实用药物与临床》
CAS
2021年第12期1129-1132,共4页
Practical Pharmacy and Clinical Remedies
基金
南通市卫健委科研项目(QA2019026)
江苏省药学会—天晴医院药学基金科研项目(Q202040)。
